Register | Login
  |   Forgot your password?

Prognosis and Response in MS

Join Dr. Jaume Sastre-Garriga, a member of the GMSA steering committee, as he discusses prognosis and treatment response in patients with MS.

Policy Issues in Managing MS

Dr. Edgardo Cristiano, from Buenos Aires, Argentina, will dicuss policy issues in the management of MS specific to optimizing treatment options in this interview.

Patient Centered Care in MS - An Expert Discussion

In this educational activity, steering committee members, Dr. Jaume Sastre-Garriga and Dr. Antonio Uccelli, discuss establishing partnerships among practitioners for best patient outcomes.

FAQs with Key Opinion Leader - Dr. Anthony Traboulsee

Interview with Gavin Giovannoni, MBBCh, PhD | United Kingdom

Dr. Gavin Giovannoni discusses the current landscape of multiple sclerosis diagnoses and prognosis, and continuity of care while at ECTRIMS 2015 in Barcelona, Spain.

Click here to visit BartsMS Blog, an informative site Dr. Giovannoni has developed for people affected by multiple sclerosis.

Interview with Jaume Sastre-Garriga, MD | Spain

Dr. Jaume Sastre-Garriga discusses the current and future landscape in patients with multiple sclerosis while at ECTRIMS 2015 in Barcelona, Spain, focusing on clinically isolated syndrome, the value of MS registries and real-world data, environmental factors in MS, risk prevention in MS, and emergent MRI techniques in assessing prognosis in patient with MS.

Interview with Jiwon Oh, MD | Canada

While at ECTRIMS 2015 we sat down with Dr. Jiwon Oh to discuss new insights into early diagnosis of MS and assessing a patient’s long-term prognosis.

Interview with Dan Selchen, MD | Canada

Dr. Dan Selchen discusses new insights into early diagnosis of MS and assessing a patient’s long-term prognosis while at ECTRIMS 2015 in Barcelona, Spain.

Panel Discussion with Ralf Gold, MD and Antonio Uccelli, MD

While at ECTRIMS 2015 in Barcelona, Spain we sat down with Dr. Ralf Gold and Dr. Antonio Uccelli to discuss hot topics in diagnosis and prognosis in MS.

FAQs with Key Opinion Leader - Dr. Gavin Giovannoni

FAQs with Key Opinion Leader - Dr. Jiwon Oh

New Look at Imaging in MS

In this educational activity, Dr. Jaume Sastre-Garriga joins Lawrence Sherman to discuss imaging in Multiple Sclerosis and the role of MRI data.

Personalized Approaches to Managing MS

Lawrence Sherman is joined by Dr. Antonio Uccelli from Genoa, Italy, to discuss a personalized approach to managing patients with MS, specific to his community.

Assessment of MS Management

Dr. Andrew Chen discusses a personalized approach to managing patients with MS.

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines

In this educational activity, Dr. Jaume Sastre-Garriga will discuss the highlights from the MAGNIMS consensus guidelines. The MAGNIMS criteria discusses how MRI can support and substitute clinical information in the diagnosis of multiple sclerosis by showing disease dissemination in space and time and by helping to exclude disorders that can mimic multiple sclerosis.

Icon To view the MAGNIMS article click here. (1.7 MB)

Interview with the Author: Positive Effect on Multiple Sclerosis with Treatment of Metabolic Syndrome

In this interview, Lawrence Sherman and Dr. Ralf Gold discuss the study, “Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis,“ which was led by researchers, Laura Negrotto and Dr. Raúl Carrea. They will also discuss the impact of the drugs on clinical biomarkers and MRI, as well as future research on immunologic effects tied to MS.

Interview with Ralf Gold, MD | Germany

Dr. Ralf Gold discuses the current and future treatment landscape for patients with Multiple Sclerosis while at ECTRIMS 2015 in Barcelona, Spain.

Additional Resources:

Expanded Disability Status Scale (EDSS) progression and magnetic resonance imaging (MRI) markers are exclusive and appropriate factors to monitor the new aim of ‘no evidence of disease activity’ (NEDA). Click here to read article in Therapeutic Advances in Neurologic Disorders: Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model

Early identification of suboptimal responses to multiple sclerosis treatment is critical for optimizing subsequent therapeutic decisions. The Rio Score  is a scoring system that consists of clinical and MRI parameters to predict suboptimal response. The Modified Rio score is a simplified version of the Rio Score, excluding expanded disability status scale progression and modified items of relapses and MRI lesions. The following articles can provide additional information.

Measures in the first year of therapy predict the response to interferon beta in MS

Scoring treatment response in patients with relapsing multiple sclerosis

Interview with Antonio Uccelli, MD | Italy

Dr. Antonio Uccelli discusses the possible near-term treatment future of patients with multiple sclerosis while at ECTRIMS 2015 in Barcelona, Spain, highlighting efforts to personalize each patient’s therapy based on MRI status and use of biomarkers as a means to select evidence-based approaches designed to maximize neuroprotection and reduce the realities of disability and brain atrophy.

Privacy Policy  |  Terms of Use  |  Contact Us  |  Site Map  |  Cookie Policy